Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 3 , Pages 290-293 , May 2012

Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer

  • Michael Staehler, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-89-7095-3722; fax: +49-89-7095-6722
    • ,
  • Nicolas Haseke, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Thomas Stadler, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Philipp Nuhn, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Alexander Roosen, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Christian G. Stief, M.D.

      Affiliations

    • Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany
    • ,
  • Ralf Wilkowski, M.D.

      Affiliations

    • Department of Radiotherapy, Klinik Bad Trissl, Oberaudorf, Germany

Received 19 November 2009 ,Revised 6 February 2010 ,Accepted 10 February 2010.

References 

  1. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute (Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site [database on the Internet]) . 2008;
  2. Motzer RJ , Hutson TE , Tomczak P , et al.  Sunitinib vs. interferon α in metastatic renal-cell carcinoma . N Engl J Med . 2007;356:115–124
  3. Cho J , Kim GE , Rha KH , et al.  Hypofractionated high-dose intensity-modulated radiotherapy (60 Gy at 2.5 Gy per fraction) for recurrent renal cell carcinoma: A case report . J Korean Med Sci . 2008;23:740–743
  4. DiBiase SJ , Valicenti RK , Schultz D , et al.  Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model . J Urol . 1997;158(3 Pt 1):746–749
  5. Lee J , Hodgson D , Chow E , et al.  A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma . Cancer . 2005;104:1894–1900
  6. Ning S , Trisler K , Wessels BW , et al.  Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts . Cancer . 1997;80(12 Suppl):2519–2528
  7. Brinkmann OA , Bruns F , Gosheger G , et al.  Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation . World J Urol . 2005;23:185–190
  8. Zingg D , Riesterer O , Fabbro D , et al.  Differential activation of the phosphatidylinositol 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells . Cancer Res . 2004;64:5398–5406
  9. Dent P , Reardon DB , Park JS , et al.  Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death . Mol Biol Cell . 1999;10:2493–2506
  10. Kasibhatla M , Steinberg P , Meyer J , et al.  Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma . Clin Genitourin Cancer . 2007;5:291–294
  11. Peters NA , Richel DJ , Verhoeff JJ , et al.  Bowel perforation after radiotherapy in a patient receiving sorafenib . J Clin Oncol . 2008;26:2405–2406
  12. Gay HA , Cavalieri R , Allison RR , et al.  Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy . Dermatol Online J . 2007;13:6
  13. Taussky D , Soulieres D . Hypofractionated radiotherapy with concomitant sunitinib—is there a radiosensitizing effect? . Can J Urol . 2009;16:4599–4600

PII: S1078-1439(10)00047-5

doi: 10.1016/j.urolonc.2010.02.006

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 3 , Pages 290-293 , May 2012

Article Tools

* Image Usage & Resolution